β-blockers and reverse remodeling: What are the implications?

American Heart Journal

Volumn 145, Issue 2, 2003, Pages 200-202

  Francis, Gary S ^a   Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODYNAMICS; HOSPITALIZATION; HUMAN; MEDICAL PRACTICE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037323525     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.106     Document Type: Editorial

References (20)

1. Zugck C, Haunstetter A, Kruger C, et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 2002;39:1615-22.
2. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 2002;39:1414-21.
3. Lee CR, Adams KF Jr, Patterson JH. Surrogate end points in heart failure. Ann Pharmacother 2002;36:479-88.
4. Levine TB, Levine AB, Keteyian SJ, et al. Reverse remodeling in heart failure with intensification of vasodilator therapy. Clin Cardiol 1997;20:697-702.
5. Lowes BD, Gill EA, Abraham WT, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999;83:1201-5.
6. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-82.
7. Cintron G, Johnson G, Francis G, et al. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(6 Suppl):V117-23.
8. Tang WHW, Larson MS, Prikazsky L, et al. Reversal remodeling following long-term carvedilol therapy is associated with improvement in survival: the Stanford carvedilol echocardiographic registry [abstract]. J Am Coll Cardiol 2002;39(2 Suppl A):141A.
9. Kawai K, Takaoka H, Hata K, et al. Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 1999;84:671-6.
10. Francis GS, Johnson TH, Ziesche S, et al. Marked spontaneous improvement in ejection fraction in patients with congestive heart failure. Am J Med 1990;89:303-7.
11. Metra M, Nodari S, Parrinello G, et al. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003;145:292-9.
12. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001;141:899-907.
13. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103:1428-33.
14. Levine TB, Levine AB, Keteyian SJ, et al. The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure. Clin Cardiol 1998;21:899-904.
15. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
16. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
17. Khattar RS, Senior R, Soman P, et al. Regression of left ventricular remodeling in chronic heart failure: comparative and combined effects of captopril and carvedilol. Am Heart J 2001;142:704-13.
18. Lim PO, MacFadyen RJ, Struthers AD. Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment? Heart 2000;83:257-61.
19. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
20. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107-14.